Organogenesis Expands Manufacturing Capacity to Support Future Growth
Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations including Massachusetts, Alabama, California, Florida, and Switzerland. The Rhode Island expansion is subject to state and local tax incentives.
Organogenesis Holdings (Nasdaq: ORGO) ha annunciato piani per espandere la propria capacità produttiva attraverso un contratto di affitto a lungo termine di una struttura di biomanifattura all'avanguardia di 122.000 piedi quadrati a Smithfield, Rhode Island. L'azienda di medicina rigenerativa, che si concentra sui mercati della Cura Avanzata delle Ferite e della Medicina Chirurgica e Sportiva, manterrà le proprie operazioni esistenti in diverse sedi, tra cui Massachusetts, Alabama, California, Florida e Svizzera. L'espansione nel Rhode Island è soggetta a incentivi fiscali statali e locali.
Organogenesis Holdings (Nasdaq: ORGO) anunció planes para expandir su capacidad de manufactura a través de un contrato de arrendamiento a largo plazo de una instalación de biomanufactura de última generación de 122,000 pies cuadrados en Smithfield, Rhode Island. La compañía de medicina regenerativa, que se centra en los mercados de Cuidado Avanzado de Heridas y Medicina Quirúrgica y Deportiva, mantendrá sus operaciones existentes en múltiples ubicaciones, incluyendo Massachusetts, Alabama, California, Florida y Suiza. La expansión en Rhode Island está sujeta a incentivos fiscales estatales y locales.
Organogenesis Holdings (Nasdaq: ORGO)는 로드아일랜드 스미스필드에 122,000 제곱피트 규모의 최첨단 바이오제조 시설을 장기 임대하여 제조 능력을 확장할 계획을 발표했습니다. 고급 상처 치료 및 외과 및 스포츠 의학 시장에 주력하는 이 regenerative medicine(재생 의학) 회사는 매사추세츠, 앨라배마, 캘리포니아, 플로리다 및 스위스를 포함한 여러 장소에서 기존 운영을 유지할 것입니다. 로드아일랜드의 확장은 주 및 지역 세금 인센티브를 조건으로 합니다.
Organogenesis Holdings (Nasdaq: ORGO) a annoncé des projets pour étendre sa capacité de production grâce à un bail à long terme d'une installation de biomanufacture à la pointe de la technologie de 122 000 pieds carrés à Smithfield, Rhode Island. L'entreprise de médecine régénérative, qui se concentre sur les marchés des Soins Avancés des Plaies et de la Médecine Chirurgicale et Sportive, maintiendra ses opérations existantes dans plusieurs établissements, y compris le Massachusetts, l'Alabama, la Californie, la Floride et la Suisse. L'expansion dans le Rhode Island est sujette à des incitations fiscales étatiques et locales.
Organogenesis Holdings (Nasdaq: ORGO) hat Pläne zur Erweiterung seiner Produktionskapazitäten durch einen langfristigen Mietvertrag für eine hochmoderne Bioproduktionsstätte mit 122.000 Quadratfuß in Smithfield, Rhode Island, angekündigt. Das Unternehmen für regenerative Medizin, das sich auf die Märkte für Fortgeschrittene Wundversorgung sowie Chirurgie und Sportmedizin konzentriert, wird seine bestehenden Betriebe an mehreren Standorten, darunter Massachusetts, Alabama, Kalifornien, Florida und die Schweiz, aufrechterhalten. Die Expansion in Rhode Island unterliegt staatlichen und lokalen Steuervorteilen.
- Significant manufacturing expansion with 122,000-square foot facility
- Strategic growth initiative to enhance production capabilities
- Potential tax incentives from state and local authorities
- None.
Insights
The expansion into a 122,000-square foot biomanufacturing facility represents a significant operational scale-up for Organogenesis. This strategic move strengthens manufacturing capabilities across multiple locations, creating a robust production network spanning six U.S. states and Switzerland. The Rhode Island facility's size suggests substantial production capacity increase, likely enabling 24/7 operations and improved supply chain efficiency.
The contingency on tax incentives indicates careful financial planning, as these benefits could significantly reduce operational costs. The location choice in Rhode Island's life sciences hub offers potential synergies with local biotech resources and talent pools. This expansion positions ORGO to meet growing market demand while potentially reducing production bottlenecks and operational risks through geographical diversification.
This facility expansion signals strong growth expectations in both Advanced Wound Care and Surgical/Sports Medicine markets. The investment in state-of-the-art biomanufacturing capabilities suggests preparation for increased market penetration and possible new product launches. With a market cap of
The strategic location in Rhode Island's biotech corridor could enhance the company's competitive position in the regenerative medicine space. The timing of this expansion, amid growing demand for advanced wound care solutions, positions ORGO to capitalize on market opportunities while maintaining quality control through owned manufacturing facilities rather than outsourcing.
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island.
“We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board. “We look forward to strengthening our industry-leading portfolio with this world class biomanufacturing facility.”
The company will continue to operate its headquarters and manufacturing facilities in Canton, Mass., as well as additional operations in Norwood, Mass., Birmingham, Ala., San Diego, Calif., St. Petersburg, Fla., and Reinach, Switzerland. The Rhode Island lease is contingent upon anticipated state and local tax incentives.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “future,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company’s products (including as a result of recent LCDs or any changes to those LCDs); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company has incurred losses in the current period and prior periods and may incur losses in the future; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (8) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (9) whether the Company is able to obtain regulatory approval for and successfully commercialize ReNu; (10) the Company may experience delays or cost overruns in its build out of the Smithfield, Rhode Island facility; and (11) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2023 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
FAQ
Where is Organogenesis (ORGO) expanding its manufacturing capacity?
How large is the new Organogenesis (ORGO) manufacturing facility in Rhode Island?
What are the current manufacturing locations of Organogenesis (ORGO)?
Is the Organogenesis (ORGO) Rhode Island facility expansion final?
